Mammalian Target of Rapamycin Inhibitor Levels Decrease Under Cenobamate Treatment.

Everolimus levels decreased following cenobamate initiation. This is likely due to CYP3A4 induction of cenobamate. We recommend monitoring of serum plasma levels of mTORi co-administered with cenobamate and adjustment of mTORi doses accordingly.